Alamar Biosciences, Inc. ALMR
30.64 USD +0.09 (+0.29%)
Regular-session close
30.64 0.00 0.00%
After hours · Nov 17, 4:01 PM ET
29.27 Day range 31.11
18.85 52-week range 39.61
- YTD
- +39.27%
- 1 year
- +39.27%
News
globenewswire.com Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations Researchers across academia and biopharma use NULISA to better stratify patients for disease progression and therapeutic response, strengthen the utility of brain-derived p-tau217 testing and expand…
seekingalpha.com Alamar Biosciences, Inc. (ALMR) Presents at 2026 UBS Global Healthcare Conference Transcript Alamar Biosciences, Inc. ( ALMR ) 2026 UBS Global Healthcare Conference November 10, 2026 5:00 PM EST Company Participants Justin McAnear - Chief Financial Officer Conference Call Participants…benzinga.com TD Cowen Maintains Buy on Alamar Biosciences, Raises Price Target to $36 TD Cowen analyst Dan Brennan maintains Alamar Biosciences (NASDAQ:ALMR) with a Buy and raises the price target from $34 to $36.
benzinga.com Alamar Biosciences Q3 2026 Earnings Call Transcript Alamar Biosciences (NASDAQ:ALMR) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Alamar Biosciences Raises FY2026 Sales Guidance from $116.000M-$120.000M to $121.000M-$123.000M vs $118.632M Est Alamar Biosciences (NASDAQ:ALMR) raises FY2026 sales outlook from $116.000 million-$120.000 million to $121.000 million-$123.000 million vs $118.632 million estimate.
benzinga.com Alamar Biosciences Q3 EPS $(0.19); Sales $33.55M Up 68% From $19.91M YoY Alamar Biosciences (NASDAQ:ALMR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. The company reported quarterly sales of $33.550…
benzinga.com Alamar Biosciences Partners With GSK For Its Use Of NULISA Platform In Trial To Evaluate Protein Signatures Regarding Disease Progression, Biological Subtypes And Treatment Response Across Respiratory, Liver, Kidney, Neurological And Autoimmune Conditions Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc…
